Table 4 The percentage of cell population in each phase of cell cycle resulted from PSS, PL, and cisplatin treatment in 4 breast cancer cell lines

MCF7

 - Untreated

73.02 ± 5.30

15.68 ± 1.53

8.90 ± 3.86

 - PSS

74.94 ± 3.65

9.13 ± 1.55 ^*

13.94 ± 2.61

 - PL

73.27 ± 4.32

7.27 ± 1.50 ^**

16.32 ± 3.97

 - Cisplatin

58.56 ± 7.39

12.00 ± 2.93

28.06 ± 6.34 ^*

T47D

 - Untreated

77.15 ± 2.00

9.07 ± 1.07

13.24 ± 1.34

 - PSS

75.99 ± 0.68

8.76 ± 1.05

14.64 ± 0.94

 - PL

83.14 ± 1.60 ^*

8.55 ± 0.98

7.98 ± 2.16

 - Cisplatin

44.47 ± 15.48

2.57 ± 0.43 ^****

52.54 ± 15.06 ^*

MDA-MB-231

 - Untreated

74.91 ± 1.22

9.34 ± 0.33

11.08 ± 3.02

 - PSS

76.29 ± 1.92

3.73 ± 1.58 ^*

12.07 ± 3.63

 - PL

70.87 ± 3.19

7.83 ± 0.77

14.48 ± 1.90

 - Cisplatin

90.12 ± 1.39 ^***

5.43 ± 1.97

2.82 ± 0.25 ^*

MDA-MB-468

 - Untreated

80.64 ± 2.70

8.19 ± 1.23

9.95 ± 1.54

 - PSS

79.83 ± 4.90

7.38 ± 2.81

11.16 ± 1.62

 - PL

78.33 ± 5.28

8.63 ± 1.93

8.67 ± 2.74

 - Cisplatin

79.62 ± 4.30

8.03 ± 1.37

9.25 ± 1.75